Related references
Note: Only part of the references are listed.Association Between Minimum Inhibitory Concentration, Beta-lactamase Genes and Mortality for Patients Treated With Piperacillin/Tazobactam or Meropenem From the MERINO Study
A. Henderson et al.
CLINICAL INFECTIOUS DISEASES (2021)
Meropenem-Tobramycin Combination Regimens Combat Carbapenem-Resistant Pseudomonas aeruginosa in the Hollow-Fiber Infection Model Simulating Augmented Renal Clearance in Critically III Patients
Rajbharan Yadav et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Is Piperacillin-Tazobactam Effective for the Treatment of Pyelonephritis Caused by Extended-Spectrum β-Lactamase-Producing Organisms?
Sima L. Sharara et al.
CLINICAL INFECTIOUS DISEASES (2020)
Prolonged Versus Intermittent Infusion of β-Lactam Antibiotics: A Systematic Review and Meta-Regression of Bacterial Killing in Preclinical Infection Models
Sofie Dhaese et al.
CLINICAL PHARMACOKINETICS (2020)
Pharmacodynamic evaluation of intermittent versus extended and continuous infusions of piperacillin/tazobactam in a hollow-fibre infection model against Klebsiella pneumoniae
Chandra Datta Sumi et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
Urinary piperacillin/tazobactam pharmacokinetics in vitro to determine the pharmacodynamic breakpoint for resistant Enterobacteriaceae
M. Gould et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2019)
Optimal Piperacillin-Tazobactam Dosing Strategies against Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae
Henrietta Abodakpi et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Optimization of a Meropenem-Tobramycin Combination Dosage Regimen against Hypermutable and Nonhypermutable Pseudomonas aeruginosa via Mechanism-Based Modeling and the Hollow-Fiber Infection Model
Cornelia B. Landersdorfer et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance A Randomized Clinical Trial
Patrick N. A. Harris et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Outcome of Patients Admitted to a Tertiary Referral Intensive Care Unit with Urosepsis Needing Source Control
Chaitra C. Rao et al.
INDIAN JOURNAL OF CRITICAL CARE MEDICINE (2018)
Pharmacodynamics of Aerosolized Fosfomycin and Amikacin against Resistant Clinical Isolates of Pseudomonas aeruginosa and Klebsiella pneumoniae in a Hollow-Fiber Infection Model: Experimental Basis for Combination Therapy
Fekade Bruck Sime et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Global epidemiology of CTX-M β-lactamases: temporal and geographical shifts in genotype
Edward R. Bevan et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Randomized controlled trial of piperacillintazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum betalactamase-producing Escherichia coli
Yu Bin Seo et al.
BMC INFECTIOUS DISEASES (2017)
Population Pharmacokinetics of Piperacillin in Nonobese, Obese, and Morbidly Obese Critically III Patients
Abdulaziz S. Alobaid et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Antimicrobial resistance in urosepsis: outcomes from the multinational, multicenter global prevalence of infections in urology (GPIU) study 2003-2013
Zafer Tandogdu et al.
WORLD JOURNAL OF UROLOGY (2016)
Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an In Vitro Infection Model
Anthony M. Nicasio et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Effect of different renal function on antibacterial effects of piperacillin against Pseudomonas aeruginosa evaluated via the hollow-fibre infection model and mechanism-based modelling
Phillip J. Bergen et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Impact of infection with extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella species on outcome and hospitalization costs
J. A. Maslikowska et al.
JOURNAL OF HOSPITAL INFECTION (2016)
Carbapenems Versus Piperacillin-Tazobactam for Bloodstream Infections of Nonurinary Source Caused by Extended-Spectrum Beta-Lactamase Producing Enterobacteriaceae
Hadas Ofer-Friedman et al.
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2015)
Interaction of Drug- and Granulocyte-Mediated Killing of Pseudomonas aeruginosa in a Murine Pneumonia Model
George Louis Drusano et al.
JOURNAL OF INFECTIOUS DISEASES (2014)
Correlations of Antibiotic Use and Carbapenem Resistance in Enterobacteriaceae
Milena McLaughlin et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Inoculum Effect on the Efficacies of Amoxicillin-Clavulanate, Piperacillin-Tazobactam, and Imipenem against Extended-Spectrum β-Lactamase (ESBL)-Producing and Non-ESBL-Producing Escherichia coli in an Experimental Murine Sepsis Model
F. Docobo-Perez et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum β-lactamase-producing and extended-spectrum β-lactamase-non-producing Escherichia coli isolates
L. Lopez-Cerero et al.
CLINICAL MICROBIOLOGY AND INFECTION (2010)
Breakpoints for extended-spectrum beta-lactamase-producing Enterobacteriacae: pharmacokinetic/pharmacodynamic considerations
A. MacGowan
CLINICAL MICROBIOLOGY AND INFECTION (2008)
Therapeutic challenges of urosepsis
F. M. E. Wagenlehner et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2008)
Extended-spectrum beta-lactamase-producing enterobacteriaceae: an emerging public-health concern
Johann D. D. Pitout et al.
LANCET INFECTIOUS DISEASES (2008)
Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances
Irith Wiegand et al.
NATURE PROTOCOLS (2008)
Extended-spectrum β-lactamases:: a clinical update
DL Paterson et al.
CLINICAL MICROBIOLOGY REVIEWS (2005)
Share Paper
